Clinical Trial Update: Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking [Phase 1]

View source ↗

Summary

Phase 1 trial evaluated AFQ056 in combination with nicotine for reducing cigarette smoking; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• AFQ056 (mavoglurant)
• Nicotine (nicotine)

Snippet

Sponsor: Novartis | Conditions: Smoking Abstinence | Phase 1 | Status: COMPLETED